TY - JOUR
T1 - Protein modification systems as cancer biomarkers and therapeutic targets
AU - Gao, Li
AU - He, Yueqin
AU - Wang, Kexin
AU - Li, Qin
AU - Nie, Litong
AU - Dai, Lunzhi
N1 - Publisher Copyright:
© The Author(s) 2026. Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]
PY - 2026/6
Y1 - 2026/6
N2 - Protein post-translational modifications (PTMs), such as acetylation, lactylation, methylation, phosphorylation, ubiquitination, and glycosylation, play central roles in regulating diverse cellular processes, including signal transduction, metabolic adaptation, chromatin organization, and proteostasis. In cancer, PTM networks are extensively rewired, with profound alterations in enzyme levels, protein modification landscapes, and crosstalk among different modification types. These changes collectively shape key cancer hallmarks, such as sustained proliferative signaling, immune evasion, and therapeutic resistance. Recent advances in proteomic technologies have enabled comprehensive mapping of PTM landscapes and their regulatory mechanisms, facilitating the identification of PTM signatures associated with tumor subtyping, disease progression, and treatment response. This review summarized biomarkers and therapeutic targets associated with dysregulated PTM regulatory pathways in cancer.
AB - Protein post-translational modifications (PTMs), such as acetylation, lactylation, methylation, phosphorylation, ubiquitination, and glycosylation, play central roles in regulating diverse cellular processes, including signal transduction, metabolic adaptation, chromatin organization, and proteostasis. In cancer, PTM networks are extensively rewired, with profound alterations in enzyme levels, protein modification landscapes, and crosstalk among different modification types. These changes collectively shape key cancer hallmarks, such as sustained proliferative signaling, immune evasion, and therapeutic resistance. Recent advances in proteomic technologies have enabled comprehensive mapping of PTM landscapes and their regulatory mechanisms, facilitating the identification of PTM signatures associated with tumor subtyping, disease progression, and treatment response. This review summarized biomarkers and therapeutic targets associated with dysregulated PTM regulatory pathways in cancer.
KW - biomarker
KW - cancer
KW - precision medicine
KW - protein modifications
KW - therapeutic target
UR - https://www.scopus.com/pages/publications/105040922996
UR - https://www.scopus.com/pages/publications/105040922996#tab=citedBy
U2 - 10.1093/pcmedi/pbag014
DO - 10.1093/pcmedi/pbag014
M3 - Review article
C2 - 42221857
AN - SCOPUS:105040922996
SN - 2096-5303
VL - 9
JO - Precision Clinical Medicine
JF - Precision Clinical Medicine
IS - 2
M1 - pbag014
ER -